Evidence map›Paper›PMID 30833579›Full record

ArticleScientific reports2019

Assessing metastatic potential of breast cancer cells based on EGFR dynamics.

Yen-Liang Liu, Chao-Kai Chou, Mirae Kim, Rohan Vasisht, Yu-An Kuo, Phyllis Ang, Cong Liu, Evan P Perillo, Yu-An Chen, Katherine Blocher and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Recent Advances in Single-Molecule Tracking and Imaging Techniques.Annual review of analytical chemistry (Palo Alto, Calif.) · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yen-Liang LiuDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Chao-Kai ChouDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mirae KimDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Rohan VasishtDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Yu-An KuoDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Phyllis AngDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, TX, USA.
Cong LiuDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Evan P PerilloDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Yu-An ChenDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Katherine BlocherDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Hannah HorngDepartment of Bioengineering, The University of Maryland, College Park, MD, USA.
Yuan-I ChenDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Duc Trung NguyenDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Thomas E YankeelovDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Mien-Chie HungDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew K DunnDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Hsin-Chih YehDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA. Tim.Yeh@austin.utexas.edu.

Funding

Comprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7M
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast CancerR01CA211615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, LIUQING · 2017 to 2021
$2.1M
An integrated imaging tool for probing EGFR subcellular trafficking in real timeR21CA193038 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI DUNN, ANDREW K, YEH, HSIN-CHIH · 2015 to 2017
$625k
NCI NIH HHS R01 CA211615NCI NIH HHS R21 CA193038NIBIB NIH HHS T32 EB007507
6 · The paper itself

Abstract

Derailed transmembrane receptor trafficking could be a hallmark of tumorigenesis and increased tumor invasiveness, but receptor dynamics have not been used to differentiate metastatic cancer cells from less invasive ones. Using single-particle tracking techniques, we  developed a phenotyping asssay named Transmembrane Receptor Dynamics (TReD), studied the dynamics of epidermal growth factor receptor (EGFR) in seven breast epithelial cell lines and developed a phenotyping assay named Transmembrane Receptor Dynamics (TReD). Here we show a clear evidence that increased EGFR diffusivity and enlarged EGFR confinement size in the plasma membrane (PM) are correlated with the enhanced metastatic potential in these cell lines. By comparing the TReD results with the gene expression profiles, we found a clear negative correlation between the EGFR diffusivities and the breast cancer luminal differentiation scores (r = -0.75). Upon the induction of epithelial-mesenchymal transition (EMT), EGFR diffusivity significantly increased for the non-tumorigenic MCF10A (99%) and the non-invasive MCF7 (56%) cells, but not for the highly metastatic MDA-MB-231 cell. We believe that the reorganization of actin filaments during EMT modified the PM structures, causing the receptor dynamics to change. TReD can thus serve as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis.

Indexed as

ActinsBreast NeoplasmsCell Line, TumorEpithelial-Mesenchymal TransitionErbB ReceptorsFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansActinsErbB Receptors

Identifiers

PMID30833579
PMCPMC6399327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.